Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B)

Vaccine

Volumn 30, Issue 11, 2012, Pages 1917-1926

  Shearer, Jeffry D ^a   Manetz, T Scott ^b,c   House, Robert V ^a  

^a A CSC Company   (United States)

^b Gene Logic Laboratories Inc   (United States)

^c MEDIMMUNE   (United States)

Author keywords

Biodefense; Botulinum neurotoxin; Preclinical safety; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; BOTULINUM ANTISERUM; RECOMBINANT BOTULINUM A VACCINE; RECOMBINANT BOTULINUM B VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOTULISM; COGNITION; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; EDEMA; ERYTHEMA; FEMALE; FOOD INTAKE; HISTOPATHOLOGY; INJECTION SITE INFLAMMATION; MALE; MORTALITY; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RISK ASSESSMENT; ULCER; VACCINATION;

ANIMALS; BACTERIAL VACCINES; BOTULINUM TOXINS; BOTULISM; DRUG EVALUATION, PRECLINICAL; FEMALE; MALE; MICE; RABBITS; VACCINES, SYNTHETIC;

EID: 84857195952     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.035     Document Type: Article

References (23)

1. Hill K.K., Smith T.J., Helma C.H., Ticknor L.O., Foley B.T., Svensson R.T., et al. Genetic diversity among botulinum neurotoxin-producing clostridial strains. J Bacteriol 2007, 189:818-832.
2. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070.
3. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004, 44:167-193.
4. Centers for Disease Control 2010 Emergency Preparedness and Response Bioterrorism. http://www.bt.cdc.gov/agent/agentlist-category.asp.
5. Dembek ZF, Smith LA, Rusnak JM. Botulinum Toxin. In: Dembek ZF, editors. Medical Aspects of Biological Warfare, rev ed. Office of the Surgeon General United States Army and Washington, DC: Borden Institute, Walter Reed Medical Center, Falls Church, VA; 2007. p. 337-53.
6. Arnon S.S., Schechter R., Maslanka S.E., Jewell N.P., Hatheway C.L. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006, 354(5):462-471.
7. Franz D.R., Pitt L.M., Clayton M.A., Hanes M.A., Rose K.J. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects 1993, 473-477. Plenum Press, New York, NY. B.R. Das Gupta (Ed.).
8. Cheng L.W., Stanker L.H., Henderson T.D., Lou J., Marks J.D. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 2009, 77(10):4305-4313.
9. Keller J.E. Characterization of new formalin-detoxified botulinum neurotoxin toxoids. Clinical Vaccine Immunol 2008, 15(9):1374-1379.
10. Smith L.A., Rusnak J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 2007, 27:303-318.
11. Smith L.A. Botulism and vaccines for its prevention. Vaccine 2009, 27:D33-D39.
12. Franciosa G., Floridi F., Maugliani a Aureli P. Differentiation of the gene clusters encoding botulinum neurotoxin type A complexes in Clostridium botulinum type A, Ab and A(B) strains. Appl Environ Microbiol 2004, 70:3192-7199.
13. Byrne M., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82:955-966.
14. Shearer J.D., Vassar M., Metcalfe K., Swiderski W., Niemuth N., Henderson I. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B). Vaccine 2010, 28:7313-7318.
15. Sutkwoski E.M., Gruber M.F. Non-clinical safety evaluations of preventative vaccines - regulatory considerations. Business Briefing: Future Drug Discovery 2003, (June):34-37.
16. World Health Organization. WHO Guidelines on Nonclinical Evaluation of Vaccines, 2005; Technical Report Series No. 927, Annex 1.
17. Wolf J.J., Kaplanski C.V., Lebron JA Nonclinical safety assessment of vaccines and adjuvants. Vaccine adjuvants, method in molecular biology 2010, vol. 626:29-40. Springer-Verlag, New York.
18. Lebron J.A., Wolf J.J., Kaplanski C.V., Ledwith B.J. Ensuring the quality, potency and safety of vaccines during preclinical development. Expert Rev. Vaccines 2005, 855-866.
19. Greenbaum S.B., Anderson J.B. Botulinum toxins. Biodefense research methodology and animal models 2006, 259-274. CSC Press, Boca Raton, FL. J.R. Swearengen (Ed.).
20. Draize JH. Dermal toxicity. In: Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics. Editorial Committee of The Association of Food and Drug Officials of the United States, Bureau of Food and Drugs, Austin, TX, 1959, p. 46-59.
21. Cardella M.A. Botulinum toxoids. Botulism: Proceeding of a Symposium 1964, 113-130. K.H. Lewis, K. Cassel (Eds.).
22. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993, 11:293-306.
23. Gupta R.K., Siber G.R. Comparison of adjuvant activities of aluminum phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals 1994, 22:53-63.